Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2 - Concepedia

Concepedia

Publication | Closed Access

Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2

82

Citations

18

References

2010

Year

William D. Hardy, Roy M. Gulick, Howard Mayer, Gerd Fätkenheuer, Mark Nelson, Jayvant Heera, Natasa Rajicic, James Goodrich

JAIDS Journal of Acquired Immune Deficiency Syndromes

Abstract

Maraviroc-containing antiretroviral regimens maintained durable responses in treatment-experienced patients with R5 HIV-1 through 96 weeks of treatment with a safety profile similar to placebo.

References

	Year	Citations

Page 1